Related references
Note: Only part of the references are listed.Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method
Daniel Normolle et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials
Weili He et al.
STATISTICS IN MEDICINE (2006)
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors
J Dupont et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors
R Salazar et al.
CLINICAL CANCER RESEARCH (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Sequential designs for phase I clinical trials with late-onset toxicities
YK Cheung et al.
BIOMETRICS (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
